Disparities in Socioeconomic Context and Association With Blood Pressure Control and Cardiovascular Outcomes in ALLHAT.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
06 08 2019
Historique:
entrez: 1 8 2019
pubmed: 1 8 2019
medline: 5 1 2021
Statut: ppublish

Résumé

Background Observational studies demonstrate that communities of low socioeconomic status have higher blood pressure and worse cardiovascular outcomes. Yet, whether the clinical outcomes resulting from antihypertensive therapy vary by socioeconomic context in a randomized clinical trial, in which participants are treated under a standard protocol, is unknown. Methods and Results We used data from ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) to study the effect of socioeconomic context, defined as the county-level median household income, of study sites. We stratified sites into income quintiles and compared characteristics, blood pressure control, and cardiovascular outcomes among ALLHAT participants in the lowest- and highest-income quintiles. Among 27 862 qualifying participants, 2169 (7.8%) received care in the lowest-income sites (quintile 1) and 10 458 (37.6%) received care in the highest-income sites (quintile 5). Participants in quintile 1 were more likely to be women, to be black, to be Hispanic, to have fewer years of education, to live in the South, and to have fewer cardiovascular risk factors. After adjusting for baseline demographic and clinical characteristics, quintile 1 participants were less likely to achieve blood pressure control (<140/90 mm Hg) (odds ratio, 0.48; 95% CI, 0.37-0.63) and had greater all-cause mortality (hazard ratio [HR], 1.25; 95% CI, 1.10-1.41), heart failure hospitalizations/mortality (HR, 1.26; 95% CI, 1.03-1.55), and end-stage renal disease (HR, 1.86; 95% CI, 1.26-2.73), but lower angina hospitalizations (HR, 0.70; 95% CI, 0.59-0.83) and coronary revascularizations (HR, 0.71; 95% CI, 0.57-0.89). Conclusions Despite standardized treatment protocols, ALLHAT participants in the lowest-income sites experienced poorer blood pressure control and worse outcomes for some adverse cardiovascular events, emphasizing the importance of measuring and addressing socioeconomic context. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00000542.

Identifiants

pubmed: 31362591
doi: 10.1161/JAHA.119.012277
pmc: PMC6761647
doi:

Substances chimiques

Antihypertensive Agents 0
Hypolipidemic Agents 0

Banques de données

ClinicalTrials.gov
['NCT00000542']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e012277

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NHLBI NIH HHS
ID : T35 HL007649
Pays : United States
Organisme : AHRQ HHS
ID : K12 HS023000
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

J Clin Hypertens (Greenwich). 2015 Sep;17(9):668-72
pubmed: 25952495
JAMA Cardiol. 2017 Jul 1;2(7):814-816
pubmed: 28593300
Am J Epidemiol. 2017 May 15;185(10):888-897
pubmed: 28449023
Ann Intern Med. 2015 Sep 1;163(5):329-38
pubmed: 26215765
Am J Prev Med. 2015 Dec;49(6):912-20
pubmed: 26590940
Hypertension. 2003 Sep;42(3):239-46
pubmed: 12925554
Hypertension. 2010 Mar;55(3):769-75
pubmed: 20100998
Circ Cardiovasc Qual Outcomes. 2014 Jul;7(4):540-9
pubmed: 24895450
Obesity (Silver Spring). 2012 Apr;20(4):862-71
pubmed: 21660076
J Hum Hypertens. 1998 Feb;12(2):91-110
pubmed: 9504351
Circ Cardiovasc Qual Outcomes. 2014 Sep;7(5):749-56
pubmed: 25074375
J Am Heart Assoc. 2019 Aug 6;8(15):e012277
pubmed: 31362591
Health Place. 2016 Sep;41:110-118
pubmed: 27583527
Am J Med. 2006 Jan;119(1):70.e9-15
pubmed: 16431192
Hypertension. 2016 Nov;68(5):1314-1320
pubmed: 27600181
J Clin Hypertens (Greenwich). 2013 Jun;15(6):404-12
pubmed: 23730989
J Clin Hypertens (Greenwich). 2013 Sep;15(9):650-4
pubmed: 24034658
Am J Hypertens. 1999 Oct;12(10 Pt 1):951-8
pubmed: 10560780
J Am Heart Assoc. 2014 Nov 14;3(6):e001029
pubmed: 25398888
Circ Cardiovasc Qual Outcomes. 2018 Jan;11(1):e004052
pubmed: 29317456
JAMA. 2002 Dec 18;288(23):2981-97
pubmed: 12479763
Health Psychol. 2003 Nov;22(6):638-42
pubmed: 14640862
Am J Hypertens. 1996 Apr;9(4 Pt 1):342-60
pubmed: 8722437
Ann N Y Acad Sci. 2010 Feb;1186:125-45
pubmed: 20201871
Hypertension. 2001 Jan;37(1):19-27
pubmed: 11208751
Am J Hypertens. 2011 May;24(5):518-29
pubmed: 21331054
JAMA. 2005 Apr 6;293(13):1595-608
pubmed: 15811979
Natl Health Stat Report. 2017 Sep;(106):1-14
pubmed: 29155688
Am J Public Health. 2007 Apr;97(4):718-24
pubmed: 17329664
Control Clin Trials. 2001 Dec;22(6):674-86
pubmed: 11738123
BMC Public Health. 2017 Dec 19;17(1):967
pubmed: 29258489
Heart. 2016 May 15;102(10):775-82
pubmed: 26864672
Circulation. 2014 Jun 17;129(24):2528-38
pubmed: 24727094
Int J Stroke. 2017 Oct;12(8):815-826
pubmed: 28387158
J Racial Ethn Health Disparities. 2017 Dec;4(6):1189-1194
pubmed: 28039604
Eur Heart J. 2009 Jun;30(11):1378-84
pubmed: 19297384
J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404
pubmed: 12461301
JAMA Cardiol. 2017 Jul 1;2(7):782-790
pubmed: 28593301
Am J Hypertens. 2016 Jan;29(1):90-5
pubmed: 25917562
BMC Health Serv Res. 2016 Jul 08;16:236
pubmed: 27391223
J Womens Health (Larchmt). 2013 Sep;22(9):724-32
pubmed: 23992103

Auteurs

Andi Shahu (A)

Department of Medicine Johns Hopkins Hospital Baltimore MD.

Jeph Herrin (J)

Section of Cardiovascular Medicine Department of Internal Medicine Yale School of Medicine New Haven CT.
Health Research & Educational Trust Chicago IL.

Sanket S Dhruva (SS)

San Francisco Veterans Affairs Medical Center San Francisco CA.
University of California, San Francisco School of Medicine San Francisco CA.

Nihar R Desai (NR)

Section of Cardiovascular Medicine Department of Internal Medicine Yale School of Medicine New Haven CT.
Center for Outcomes Research and Evaluation Yale-New Haven Hospital New Haven CT.

Barry R Davis (BR)

Coordinating Center for Clinical Trials University of Texas School of Public Health Houston TX.

Harlan M Krumholz (HM)

Section of Cardiovascular Medicine Department of Internal Medicine Yale School of Medicine New Haven CT.
Center for Outcomes Research and Evaluation Yale-New Haven Hospital New Haven CT.
Department of Health Policy and Management Yale School of Public Health New Haven CT.

Erica S Spatz (ES)

Section of Cardiovascular Medicine Department of Internal Medicine Yale School of Medicine New Haven CT.
Center for Outcomes Research and Evaluation Yale-New Haven Hospital New Haven CT.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH